Mallinckrodt just got its hand slapped for illegally protecting an 85,000% price hike
The view from Endpoints
More than three years ago, Questcor paid Novartis $135 million to gain US rights to a therapy that posed a direct threat to its Acthar drug franchise. It was the deal of the decade, blocking a competitor that could have carved into a blockbuster franchise. Andrew Pollack at The New York Times laid it all out in simple terms in a venue that no one who cared about drug pricing could have missed.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.